Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
Mark Ross Middleton, Jean‐Jacques Grob, Neil K. Aaronson et al. · Journal of Clinical Oncology · 2000
PURPOSE: To compare, in 305 patients with advanced metastatic melanoma, temozolomide and dacarbazine (DTIC) in terms of overall survival, progression-free survival (PFS), objective response, and safety, and to assess health-related quality of life (QOL) and pharmacokinetics of both drugs and their metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboximide (MTIC). PATIENTS AND METHODS: Patients were randomized to receive either oral temozolomide at a starting dosage of 200 mg/m(2)/d for 5 days every 28 days or intravenous (IV) DTIC at a starting dosage of 250 mg/m(2)/d for 5 days every 21 days. RESULTS: In the intent-to-treat population, median survival time was 7.7 months for patients treated with temozolomide and 6.4 months for those treated with DTIC (hazards ratio, 1.18; 95% confidence interval [CI], 0.92 to 1.52). Median PFS time was significantly longer in the temozolomide-treated group (1.9 months) than in the DTIC-treated group (1.5 months) (P =.012; hazards ratio, 1.37; 95% CI, 1.07 to 1.75). No major difference in drug safety was observed. Temozolomide was well tolerated and produced a noncumulative, transient myelosuppression late in the 28-day cycle. The most common nonhematologic toxicities were mild to moderate nausea and vomiting, which were easily managed. Temozolomide therapy improved health-related QOL; more patients showed improvement or maintenance of physical functioning at week 12. Systemic exposure (area under the curve) to the parent drug and the active metabolite, MTIC, was higher after treatment with oral temozolomide than after IV administration of DTIC. CONCLUSION: Temozolomide demonstrates efficacy equal to that of DTIC and is an oral alternative for patients with advanced metastatic melanoma.
Cited by 1,272 works. doi:10.1200/jco.2000.18.1.158
Authors
- Mark Ross Middleton
- Jean‐Jacques Grob
- Neil K. Aaronson
- Gerhard Fierlbeck
- Wolfgang Tilgen
- Simone Seiter
- Martin Eric Gore
- Steinar Aamdal
- Jonathan Simon Cebon
- A. Coates
- Brigitte Dréno
- M. Henz
- Dirk Schadendorf
- Uwe Fraass
- Paul Statkevich
- ML Müller
- N. Thatcher
References
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Trends in Cancer Incidence, Survival and Mortality
- Prognostic factors in 1,521 melanoma patients with distant metastases.
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
- Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
- Phase I trial of temozolomide using an extended continuous oral schedule.
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours
- Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
- Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
- The charing cross hospital experience with temozolomide in patients with gliomas